BridgeBio Pharma, Inc. (BBIO) stock forecast and price target
Price $78.30 · data as of November 13, 2026
12-month price target
Average target$107.00
Upside / downside+36.7%
Analysts20
ConsensusStrong buy
Low $80.00Average $107.00High $156.00
Gold marker: average target · white marker: today’s price ($78.30)
Analyst ratings
Strong buy 5Buy 14Hold 3Sell 0Strong sell 0
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $-2.45 | +35.4% | $1.1B |
| Next fiscal year ends December 31, 2027 | $-0.27 | +88.8% | $1.7B |
| Next quarter ends December 31, 2026 | $-0.50 | +46.3% | $304M |
| Quarter after ends March 31, 2027 | $-0.37 | +56.2% | $338M |
Consensus of the analysts covering BridgeBio Pharma, updated daily. In the last 30 days 5 estimates were raised and 0 lowered.
Frequently asked questions
What is the BridgeBio Pharma stock price target?
The average 12-month target from 20 analysts is $107.00, 36.7% above the current price of $78.30 Targets range from $80.00 to $156.00.
Is BridgeBio Pharma a buy according to analysts?
The consensus rating is “Strong buy” (5 strong buy, 14 buy, 3 hold). Ratings are opinions, not guarantees; this is not investment advice.
How much is BridgeBio Pharma expected to earn?
Analysts expect EPS of $-2.45 for the fiscal year ending December 31, 2026 and $-0.27 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.